Search
for

    GlossaryEctodysplasin A2 Receptor

    regulates development of skin, hair, and ectodermal tissues

    The Ectodysplasin A2 Receptor (EDA2R) is a protein found on the surface of certain cells that plays a crucial role in the development of skin, hair, and other ectodermal tissues. Mutations in the gene encoding this receptor can lead to conditions like ectodermal dysplasia, which can result in abnormalities in hair growth, skin texture, and dental development.

    Related Terms

    Research

    5 / 357 results

    Community Join

    5 / 1000+ results

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  40 upvotes 6 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community Fluridil degrades the androgen receptor.

      in Research/Science  12 upvotes 9 months ago
      Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.

      community DLQ01: A Better "Minoxidil" PGF2a synthetic analogue.

      in Research/Science  3 upvotes 1 year ago
      DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  8 upvotes 8 months ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.